X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (34) 34
humans (34) 34
male (33) 33
middle aged (28) 28
aged (26) 26
index medicus (24) 24
adult (16) 16
double-blind method (16) 16
follow-up studies (14) 14
medicine, general & internal (13) 13
abridged index medicus (11) 11
risk (10) 10
risk factors (10) 10
drug therapy (9) 9
myocardial infarction (9) 9
adolescent (8) 8
cardiovascular diseases (8) 8
care and treatment (8) 8
drug therapy, combination (8) 8
cardiovascular disease (7) 7
clinical trials (7) 7
life sciences (7) 7
young adult (7) 7
cardiovascular diseases - prevention & control (6) 6
disease (6) 6
dosage and administration (6) 6
prevention (6) 6
research (6) 6
therapy (6) 6
treatment outcome (6) 6
[ sdv ] life sciences [q-bio] (5) 5
aged, 80 and over (5) 5
anticoagulants (5) 5
cardiac & cardiovascular systems (5) 5
coronary artery disease (5) 5
heart attacks (5) 5
kaplan-meier estimate (5) 5
medical and health sciences (5) 5
medicin och hälsovetenskap (5) 5
mesh : aged (5) 5
mesh : female (5) 5
mesh : follow-up studies (5) 5
mesh : humans (5) 5
mesh : male (5) 5
mesh : middle aged (5) 5
proportional hazards models (5) 5
prospective studies (5) 5
stroke (5) 5
angina (4) 4
benzaldehydes - adverse effects (4) 4
cardiovascular diseases - mortality (4) 4
cerebral infarction (4) 4
cholesterol (4) 4
comparative analysis (4) 4
coronary disease - drug therapy (4) 4
diabetes (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
endocrinology & metabolism (4) 4
heart diseases (4) 4
hemorrhage - chemically induced (4) 4
insulin (4) 4
insulin glargine (4) 4
lipids (4) 4
lipoprotein (4) 4
medical research (4) 4
mesh : double-blind method (4) 4
mortality (4) 4
otorhinolaryngology (4) 4
oximes - adverse effects (4) 4
patient outcomes (4) 4
patients (4) 4
teachers (4) 4
thromboembolism (4) 4
venous thromboembolism (4) 4
venous thromboembolism - drug therapy (4) 4
warfarin (4) 4
warfarin - adverse effects (4) 4
acute coronary syndrome (3) 3
acute coronary syndrome - drug therapy (3) 3
acute coronary syndromes (3) 3
anticoagulants - administration & dosage (3) 3
anticoagulants - adverse effects (3) 3
anticoagulants - therapeutic use (3) 3
atherosclerosis (3) 3
benzaldehydes - administration & dosage (3) 3
benzimidazoles (3) 3
benzimidazoles - adverse effects (3) 3
child (3) 3
complications and side effects (3) 3
coronary artery disease - drug therapy (3) 3
coronary disease (3) 3
coronary disease - mortality (3) 3
coronary heart disease (3) 3
dabigatran (3) 3
diabetes mellitus, type 2 - complications (3) 3
disorders (3) 3
dysfunction (3) 3
fatty acids (3) 3
hemorrhage (3) 3
hypercortisolism (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 799 - 808
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article